In a significant development for mental health treatments, Enveric Biosciences (NASDAQ: ENVB) has secured its first U.S. patent for a novel series of compounds that could transform how we approach neuropsychiatric disorders. The company’s…
Read More
Enveric Biosciences has secured its first U.S. patent for the EVM401 Series, a novel collection of non-hallucinogenic, mescaline-derived compounds. These compounds are designed to address addiction, ADHD anxiety, and other…
Read More
New patent for mescaline derivative compounds broadens Enveric's potential to develop neuroplastogen therapeutics for addiction and neuropsychiatric disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a…
Read More
The treatment landscape for joint diseases like osteoarthritis and rheumatoid arthritis is poised for a significant breakthrough, thanks to an innovative licensing deal between Enveric Biosciences and Restoration Biologics. The…
Read More
On Tuesday, Enveric Biosciences’ wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements with Restoration Biologics LLC, a biotechnology company focused on treating joint disease. The companies have executed…
Read More
Enveric Biosciences announced the issuance of two new patents from the US Patent and Trademark Office (USPTO) supporting its EVM301 and EVM201 series compounds. These patents increase the total number…
Read More
Psychedelics biotech company Enveric Biosciences completed preclinical pharmacokinetic (PK) studies for its leading drug candidate EB-003 aimed at treating depression and anxiety without causing hallucinations. EB-003 is a neuroplastic and…
Read More
Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech…
Read More
Enveric Biosciences licenses its EB-002 drug candidate to MycoMedica Life Sciences, focusing on mental health treatment advancements. Enveric receives up to $62M in milestone payments and royalties, while prioritizing its…
Read More
Enveric Biosciences Inc, a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio. This latest additions bring Enveric's total to nine issued…
Read More
